Sort
10,766 grants matching “checkpoint inhibitor”
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
$148,742Abby Margaret Green · Children'S Hosp Of Philadelphia · K08 · FY2016 · CA
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
$148,742Abby Margaret Green · Washington University · K08 · FY2020 · CA
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
$148,742Abby Margaret Green · Children'S Hosp Of Philadelphia · K08 · FY2017 · CA
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
$148,539Katharina Hopp · University Of Colorado Denver · K01 · FY2019 · DK
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
$148,539Katharina Hopp · University Of Colorado Denver · K01 · FY2020 · DK
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
$148,539Katharina Hopp · University Of Colorado Denver · K01 · FY2022 · DK
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
$148,539Katharina Hopp · University Of Colorado Denver · K01 · FY2021 · DK
Evaluate the role of extracellular vesicles in tumor microenvironment modulation
$148,500Ikjot Singh Sohal · University Of North Texas · R03 · FY2025 · CA
Tumor-Infiltrating Lymphocytes in Anal Cancer and Pre-malignant Anal Lesions
$148,457Staci L Sudenga · Vanderbilt University Medical Center · K07 · FY2019 · CA
Tumor-Infiltrating Lymphocytes in Anal Cancer and Pre-malignant Anal Lesions
$148,457Staci L Sudenga · Vanderbilt University Medical Center · K07 · FY2018 · CA
Tumor-Infiltrating Lymphocytes in Anal Cancer and Pre-malignant Anal Lesions
$148,457Staci L Sudenga · Vanderbilt University Medical Center · K07 · FY2022 · CA
Tumor-Infiltrating Lymphocytes in Anal Cancer and Pre-malignant Anal Lesions
$148,457Staci L Sudenga · Vanderbilt University Medical Center · K07 · FY2021 · CA
Tumor-Infiltrating Lymphocytes in Anal Cancer and Pre-malignant Anal Lesions
$148,457Staci L Sudenga · Vanderbilt University Medical Center · K07 · FY2020 · CA
Core C Mouse Model Core
$148,410Alain Charest · Massachusetts General Hospital · P01 · FY2018 · CA
Core C Mouse Model Core
$148,410Alain Charest · Massachusetts General Hospital · P01 · FY2021 · CA
Core C Mouse Model Core
$148,410Alain Charest · Massachusetts General Hospital · P01 · FY2020 · CA
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
$148,334Owen S Fenton · Univ Of North Carolina Chapel Hill · R21 · FY2025 · EB
Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia.
$148,306Anthony Kelleher · University Of New South Wales · R21 · FY2021 · AI
Exosomal Based micro RNA delivery for Resistant Lung Cancer
$148,000Mandip Singh Sachdeva · Florida Agricultural And Mechanical Univ · R16 · FY2023 · GM
Exosomal Based micro RNA delivery for Resistant Lung Cancer
$148,000Mandip Singh Sachdeva · Florida Agricultural And Mechanical Univ · R16 · FY2025 · GM
Exosomal Based micro RNA delivery for Resistant Lung Cancer
$148,000Mandip Singh Sachdeva · Florida Agricultural And Mechanical Univ · R16 · FY2024 · GM
Phase 2 Irinotecan for Treatment of p53 WT Gastric Adenocarcinoma
$147,940Manish A Shah · Weill Medical Coll Of Cornell Univ · R01 · FY2010 · FD
Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer
$147,902Laurie H Glimcher · Dana-Farber Cancer Inst · P30 · FY2024 · CA
Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression
$147,825Venkataswarup Tiriveedhi · Tennessee State University · U54 · FY2020 · CA
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
$147,823Chun Wang · Trekka Therapeutics, Llc · R41 · FY2023 · CA